CompaniesInspirna

Inspirna

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

3

As Collaborator

1

Total Enrollment

4,805

By Phase

NA: 1PHASE2: 1PHASE1: 2

By Status

COMPLETED: 2NOT_YET_RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
NCT02922764
NCT03597581
Hover over trial bars to see details

Recent Trials

NCT06339125Collaborator
Predictive Analytics and Computer Visualization Enhances Patient Safety to Prevent Falls
NANot yet recruiting
4,500 participants
Started: May 31, 2024 · Completed: Jul 31, 2025
NCT05983367Lead Sponsor
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
PHASE2Active, not recruiting
70 participants
Started: Oct 10, 2023 · Completed: Mar 31, 2025
NCT03597581Lead Sponsor
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
PHASE1Completed
89 participants
Started: Jun 5, 2018 · Completed: Mar 31, 2025
NCT02922764Lead Sponsor
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
PHASE1Completed
146 participants
Started: Nov 1, 2016 · Completed: Jan 22, 2025
Funding History (6)
D/A
Aug 29, 2022
Filing
D
Jul 11, 2022
Filing
D
Feb 24, 2021
Filing
D
Oct 10, 2018
Filing
D
Jun 16, 2016
Filing
D
Aug 18, 2015
Filing